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CRITICAL ISSUES IN DEEP VEIN
THROMBOSIS PREVENTION
—J.A. Caprini, MD, Chicago, Ill
Despite a great deal of literature including thousands of
studies showing the value of thrombosis prophylaxis inmedical and surgical patients, only 50% of the patients “at
risk” for thromboembolism worldwide receive appropriate
prophylaxis. Although there is a great fear of bleeding from
prophylactic anticoagulants, large studies have shown that
people die from thrombosis without prophylaxis rather
than bleeding from anticoagulation. These statistics are
astonishing given the fact that approximately 900,000 in-
dividuals suffer venous thromboembolism (VTE) in the
United States yearly including 300,000 deaths. The major-
ity of VTE events occur after discharge where prophylaxis is
uncommon. The expense and inconvenience of out-of-
hospital prophylaxis and lack of randomized control trials
(RCTs) for most patient groups have limited this approach.
A further problem is health care providers have been taught
to follow CHEST consensus guidelines that are a good
source of RCT data but do not apply to many patients in
clinical practice.
Part of the solution is to perform individual risk
assessment for each patient and calculate a score that has
been shown to correlate with the 30-day incidence of
imaging-proven clinical VTE events. The score needs to
be linked to a care pathway that is mandatory but in-
cludes a provision to opt out for valid contraindications.
The second approach is to expand and develop real world
clinical databases and have a section in the CHEST
guidelines document that analyzes and rates these data-
bases. Furthermore recommendations and clinical care
plans based on these databases can be suggested. Me-
chanical methods of prophylaxis have to be critically
analyzed and differences between stockings and pneu-
matic devices that have been identified in the literature
need to be widely disseminated. There needs to be a
method developed to track compliance with pneumatic
devices and also standardize them. Head to head studies
need to be done to see which of several approaches has
the best efficacy (long leg, short leg, uniform compres-
sion, sequential compression, rapid inflation).
Finally, the most important need for the prophylaxis
field is the development of safer but effective modalities.
Research involving the P-selectin or its ligand, PSGL-1, (a
leukocyte cellular adhesion molecule) is a critical issue
because preliminary data have shown that these compounds
have been shown to be effective in reducing inflammation
and thrombus resolution comparable to the low molecular
weight heparin in animals.
CRITICAL ISSUES
1. The use of individual risk assessment as a guide to
thrombosis prophylaxis including risk-scoring tied to
30-day known thrombosis rates to identify which pa-
tients would benefit from out-of-hospital prophylaxis.
2. Development of studies designed to explore new anti-
coagulants including the value of P-selectin inhibition as
a possible replacement for lowmolecular weight heparin
for thrombosis prophylaxis.
3. Meta-analysis of clinical databases to develop clinical
guidelines to supplement the CHEST consensus guide-
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dates for RCTs.
4. Standardization of International Policy Committee in-
cluding studies to determine the optimal characteristics
of the ideal device and electronic methods to streamline
and facilitate compliance.
5. Using the electronic medical record software to collect
risk data, suggest care pathways, and track long-term
outcomes and correlate them with risk score and pro-
phylaxis regime.
THE EFFECTIVENESS OF DEEP VEIN
THROMBOSIS PREVENTION
—Mark H. Meissner, MD, Seattle, Wash
Venous thromboembolism (VTE) is the second most
common complication among hospitalized patients and the
most common preventable cause of hospital death. Current
guidelines suggest that all hospitals have an active written
strategy for the prevention of VTE.1 Although there con-
tinues to be debate regarding individual vs group-specific
thromboprophylaxis models, the current American College
of Chest Physicians consensus guidelines support group-
specific thromboprophylaxis (Table). This is based on ob-
servations that the principal determinant of thromboem-
bolic risk is the indication for hospitalization; virtually all
randomized clinical trials have been based upon group risk
assignment; and complicated individual risk assessment
models may decrease physician compliance.1
The vast majority of thromboprophylaxis trials have
used venographically detected deep venous thrombosis
(DVT) as a surrogate marker for the patient-important
endpoints of symptomatic DVT, symptomatic pulmonary
embolism (PE), and fatal PE. Pharmacological prophylaxis
reduces the risk of asymptomatic DVT and symptomatic
Table. Group prophylaxis strategies adapted from Geerts
et al.1
Thromboembolic risk
DVT risk without
prophylaxis
Recommended
prophylaxis
Low
Minor surgery in mobile
patients
10% Early ambulation
Fully mobile medical patients
Moderatea LMWH or
Most general, gynecologic,
and urology patients
10% to 40% LDUH bid/tid
or
Medical patients, ill or non-
mobile
Fondaparinux
Higha
Hip/knee arthroplasty, hip
fracture
LMWH or
Major trauma 40% to 80% Fondaparinux or
Spinal cord injury VKA
bid, Twice a day; DVT, deep venous thrombosis; LDUH, low dose unfrac-
tionate heparin; LMWH, low molecular weight heparin; tid, three times a
day; VKA, vitamin K antagonist.
aConsider mechanical prophylaxis in patients with high bleeding risk; switch
to anticoagulant prophylaxis when bleeding risk decreases.VTE by 60% to 70% in general surgery patients (unfraction-
ated heparin [UFH], low molecular weight heparin
[LMWH]),1 by 70% to 76% in orthopedic patients
(LMWH, warfarin),2 and by 45% in medical patients who
are acutely ill (UFH, LMWH).3 Thromboprophylaxis with
UFH, LMWH, or fondaparinux is a strong recommenda-
tion for moderate and high-risk patients of general surgery
(grade 1A) and combined pharmacological and mechanical
prophylaxis should be considered in very high-risk patients
(grade 1C). Prophylaxis with LMWH, fondaparinux, or
adjusted dose vitamin K antagonist similarly receives a
strong recommendation (grade 1A) among patients under-
going hip or knee arthroplasty.
Despite the fact that few clinical trials are powered to
demonstrate a reduction in the patient, important out-
comes of symptomatic VTE or death, there is a strong
relationship between systematically detected DVT and
these clinically relevant acute outcomes. In a meta-analysis
of eight studies comparing LMWH prophylaxis with pla-
cebo in patients who received general surgery, LMWH
heparin was not only associated with a 72% relative risk
reduction in the primary endpoint of imaging-detected
DVT, but with similar 71% and 75% relative risk reductions
in the incidence of symptomatic VTE and PE.4 Significant
decreases in fatal PE among patients randomized to UFH
have also been demonstrated.5 Meta-analysis of 52 hip
arthroplasty trials including 10,292 patients also demon-
strated a significant reduction in symptomatic PE, although
such trials would need to include over 100,000 patients to
demonstrate a 50% reduction in fatal pulmonary embo-
lism.2 In contrast, although prophylaxis in patients who are
acutely ill medically decreases the risk of imaging-detected
DVT, a reduction in symptomatic DVT3 and pulmonary
embolism6 has not clearly been demonstrated.
Despite the importance of postoperative VTE, the as-
sociated mortality is only 0.1% to 1.0% and the long-term
consequences of the postthrombotic syndrome (PTS)
could in fact be a greater socioeconomic problem.7 If
asymptomatic postoperative DVT leads to PTS, effective
thromboprophylaxis would be an important means of re-
ducing the incidence of severe chronic venous disease. The
well-recognized association between symptomatic DVT
and PTS favors such a relationship. However, several
largely theoretical factors suggest that postoperative DVT
may be associated with a lower risk of PTS than that
developing in other settings. The long-term importance of
small, asymptomatic, nonocclusive and largely distal
thrombi can certainly be questioned. Although some8 have
found no relationship between thrombus location and the
development of PTS, others7,9 have demonstrated PTS to
occur 4 to 6 times more often among those with proximal
in comparison to distal thrombi. Furthermore, symptom-
atic postoperative thrombi have been associated with a
more rapid rate of recanalization and significantly lower risk
of recurrence,10 well-recognized factors in the develop-
ment of the PTS.
Unfortunately, PTS has not been included as a primary
outcome measure in any randomized trials evaluating VTE
